PHAT | Phathom Pharmaceuticals Company profile
Company profilePhathom Pharmaceuticals is a late clinical-stage biopharmaceutical company focused on developing and commercializing new treatments for GI disorders. We have licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a potassium competitive acid blocker (P-CAB) in late clinical-stage development for the treatment of gastric acid-related disorders. Vonoprazan has the potential to be the first gastric anti-secretory agent from a new class approved in the United States, Europe, or Canada in over 30 years. Address100 Campus Drive | NotesJump to (Finance sites)         ResearchInvestor pageinvestors.phathompharma.comIf you are looking for News & events, Press Release, they are available on their Investors Relationssite. Their Official Profiles  Support this projectIf you want to help pay for server cost or for improving this tool. You can send it via Paypal. Social MediaRecommended Books Buy on Amazon Want to know the strategies of successful swing trading? This friendly guide covers the ins and outs of this risky but profitable investing approach, explaining all the basics in plain English. You'll see how to use the two investment approaches - technical and fundamental analysis - to indentify promising securities in strongly trending markets. In addition, this guide covers how to calculate investment returns and, most important, how to manage your portfolio's risk. Take advantage of price swings in strongly trending securities and pump up your portfolio! |